• FDA removed the partial clin­i­cal hold based upon agree­ment on revisions to the CANOVA study protocol, in­clud­ing new risk mitigation measures, protocol-specified guidelines and updated futility criteria
• The t(11;14) genetic bio­marker is among the most common and routinely tested genetic ab­nor­mal­i­ties in patients with multiple myeloma¹

North Chicago, IL (Press Release) – AbbVie (NYSE: ABBV), a research-based global bio­pharma­ceu­tical com­pany, today announced that the U.S. Food and Drug Admin­istra­tion (FDA) has lifted the partial clin­i­cal hold placed on CANOVA (M13-494), a Phase 3 trial eval­u­ating veneto­clax (VENCLEXTA® OR VENCLYXTO®) for the inves­ti­ga­tional treat­ment of re­lapsed / refractory multiple myeloma. The CANOVA trial eval­u­ates veneto­clax in com­bi­na­tion with dexa­meth­a­sone versus poma­lido­mide in com­bi­na­tion with dexa­meth­a­sone in patients with re­lapsed / refractory multiple myeloma pos­i­tive for the translocation (11;14) ab­nor­mal­ity. The t(11;14) genetic bio­marker …

North Chicago, IL (Press Release) – AbbVie (NYSE: ABBV), a research-based global bio­pharma­ceu­tical com­pany, today announced the U.S. Food and Drug Admin­istra­tion (FDA) has placed a partial clin­i­cal hold on all clin­i­cal trials eval­u­ating veneto­clax (VENCLEXTA®/​VENCLYXTO®) for the inves­ti­ga­tional treat­ment of multiple myeloma. The partial clin­i­cal hold follows a review of data from the ongoing Phase 3 BELLINI trial (M14-031), a study in re­lapsed / refractory multiple myeloma, in which a higher proportion of deaths was observed in the veneto­clax arm compared to the control arm of the trial. As a result of …

The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) is now history, but there's still plenty of news to report from the meeting.

In this edition of the Beacon's ASCO multiple myeloma updates, the focus is on pre­sen­ta­tions that took place the last two days of the ASCO meet­ing – this past Monday and Tuesday – and which con­cerned poten­tial new multiple myeloma ther­a­pies.

There was a block of oral pre­sen­ta­tions related to poten­tial new myeloma ther­a­pies that took place Tuesday morning, and all those pre­sen­ta­tions are covered in this article. …

Good morning, myeloma world.

It's Monday, and the weekend definitely is over. The vigorous activity in our email inbox is making that eminently clear. But, with the week still so young, there isn't much new myeloma research for us to review with you. In fact, we have just two new studies that we'd like to discuss today.

Both studies are by European researchers who have compiled and analyzed retrospective data on some important topics.

One study out of Portugal looks at the use of Revlimid (lenalidomide) to treat multiple myeloma patients who …

A session last Sunday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting featured a num­ber of poster pre­sen­ta­tions re­lated to mul­ti­ple myeloma.

During “poster sessions” at conferences such as the ASCO meeting, re­search re­­sults are made avail­able for review by meeting attendees in the form of posters, each of which summarizes the re­­sults of a single study. Each poster is typ­i­cally about two feet high by three or four feet in length, and all posters during a ses­sion are dis­played throughout a large conference hall.

Most of the myeloma-related …

This year’s Congress of the European Hematology Association (EHA) is cur­rent­ly being held in Stockholm. It started earlier this week and will run through Sunday, June 16.

A substantial amount of myeloma-related research will be presented during the EHA meeting during both oral presentations and poster pre­sen­ta­tions.

This article summarizes some of the important myeloma-related findings that are expected to be presented during poster sessions today and to­mor­row. A previous article covered the key findings that will be pre­sented during oral pre­sen­ta­tions.

The studies covered in this article are primarily ones …